This case report describes a patient with non-dysplastic Barrett’s esophagus whose high-risk TissueCypher result prompted shortened surveillance. A follow-up endoscopy six months later identified high-grade dysplasia, enabling escalation to appropriate treatment.

Validate use of the 40-gene expression profile (GEP) to identify patients with National Comprehensive Cancer Network (NCCN) high-risk (HR) cutaneous squamous cell carcinoma (cSCC) who are at increased risk for local recurrence (LR) and metastasis, despite negative margins after surgical resection.

This multicenter study compared TissueCypher’s molecular risk classification with a traditional clinical risk model in patients with Barrett’s esophagus. The study highlights how TissueCypher can provide distinct risk information to support more personalized surveillance and treatment decisions.

This multicenter study evaluated how TissueCypher results influenced surveillance recommendations for patients with Barrett’s esophagus. Physicians changed surveillance intervals in 55% of cases, supporting more personalized, risk-aligned patient management.

Two gene expression profile (GEP) tests, the CP-GEP and the 31-GEP, have been developed to identify patients at low risk of SLN positivity who may consider avoiding SLNB. We analyzed the accuracy of the CP-GEP and 31-GEP in identifying patients with <5% risk of SLN positivity across the five validation studies of the CP-GEP and four validation studies of the 31-GEP in T1-T2 tumors.

Although most patients with cutaneous melanoma (CM) will have a negative sentinel lymph node biopsy (SLNB), up to 20%-30% of these patients will recur. The 31-gene expression profile (31-GEP) test has been prospectively validated to identify patients at low (Class 1A), intermediate (Class 1B/2A), and high (Class 2B) risk of SLN positivity and recurrence.

National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for patients with > 10% risk of positivity, consider SLNB with 5–10% risk, and foregoing with < 5% risk. The integrated 31-gene expression profile (i31-GEP) algorithm combines the 31-GEP with clinicopathologic variables, estimating SLN positivity risk.

This prospective study confirmed the performance and clinical utility of the i31-SLNB for improving risk-aligned care and demonstrated a significantly reduced SLNB performance rate when incorporating the i31-SLNB into clinical decision-making.

Data from multiple studies was systematically reviewed and analyzed to assess the 31-GEP test’s efficacy in predicting melanoma patient outcomes. Our findings suggest that the 31-GEP test may improve risk prediction when used alongside standard clinical and pathological assessments. By using 31-GEP, physicians may be better able to make more informed decisions about treatment and follow-up care, potentially improving outcomes for melanoma patients.

DecisionDx-SCC further stratified immune suppressed patients with T2a tumors into those with more favorable (Class 1 test result; 3-yr MFS of 83%) and less favorable survival (Class 2A/2B test result; 3-yr MFS of 57%). Given the study data, treatment intensification such as ART should be strongly considered in immune suppressed patients with BWH T2a SCC tumors guided by DecisionDx-SCC test results.